Cyclophosphamide Powder Cas No.50-18-0

Cyclophosphamide Powder Cas No.50-18-0

Product Name: Cyclophosphamide (CTX)
Product Source: Synthetic
Specification: ≥99%
CAS No.: 50-18-0
Molecular Formula: C₇H₁₅Cl₂N₂O₂P
Molecular Weight: 261.09 g·mol⁻¹
Testing Method: HPLC
Active Ingredient: Cyclophosphamide
Product Characteristics: White crystalline powder
Product Packaging: 1kg/bag; 25kg/drum; Customizable
Storage Conditions: Store in a cool, dry place under sealed conditions.
Shelf Life: 24 months
Send Inquiry

Cyclophosphamide API Powder CAS 50-18-0

High-Purity Oxazaphosphorine Alkylating Agent For Cytotoxic & Immunosuppressive Formulations

CAS Number: 50-18-0
Molecular Formula: C7H15Cl2N2O2P
Molecular Weight: 261.08 g/mol
Assay Standard: ≥ 99.0% (USP/EP Grade)

1. API Characterization & Manufacturing Value

Cyclophosphamide (CAS No. 50-18-0), commonly designated as CTX, is a synthetic nitrogen mustard derivative belonging to the oxazaphosphorine class of alkylating agents. Operating as a pharmacologically inactive prodrug, it relies on hepatic biotransformation to exert its potent antitumor and immunosuppressive therapeutic effects. Manufactured under strict cGMP protocols at Xi'an Tihealth, our Cyclophosphamide crystalline powder achieves a validated HPLC purity of ≥99.0%.

This pharmaceutical-grade API serves as a cornerstone in the formulation of cytotoxic chemotherapy and specialized immunosuppressive regimens, meeting the exacting standards of global pharmacopoeias for managing lymphoproliferative disorders and severe autoimmune pathologies. We ensure low residual solvent levels and optimized crystalline consistency, making it an ideal starting material for both liquid injectables and lyophilized parenteral powders.

2. Technical Data Sheet (TDS) & Specifications

Quality Parameter Specification Limit (USP / EP Grade)
Physical Appearance White crystalline powder or fine crystal aggregates
Assay (HPLC, Anhydrous Basis) 99.0% – 101.0%
Related Substances (HPLC) Single Impurity ≤ 0.10%; Total Impurities ≤ 0.50%
Water Content (Karl Fischer) ≤ 3.0% (Monohydrate form verified)
Heavy Metals (ICP-MS) ≤ 10 ppm (Compliant with ICH Q3D)
Residual Solvents Strictly controlled within ICH Q3C limits
Lyophilization Suitability Optimized for rapid reconstitution and cake integrity

3. Pharmacodynamics & Metabolic Mechanism of Action

Hepatic Biotransformation

As a specialized prodrug, CTX is hydroxylated in the liver by cytochrome P450 enzymes (predominantly CYP2B6 and CYP3A4) to form 4-hydroxycyclophosphamide. This active intermediate exists in dynamic equilibrium with its tautomer, aldophosphamide.

DNA Alkylation & Cross-Linking

Aldophosphamide spontaneously cleaves into the primary effector, phosphoramide mustard. This highly reactive alkylating moiety induces interstrand and intrastrand DNA cross-links at the N-7 position of guanine residues, irreversibly disrupting the double helix.

Cellular Apoptosis Induction

The resulting cross-linkage inhibits DNA replication and RNA transcription, triggering targeted apoptosis in rapidly proliferating malignant tumor clones and hyperactive autoimmune lymphocytes (T and B cells).

4. Core Pharmaceutical Applications

  • Oncology Formulations: The foundational active pharmaceutical ingredient for manufacturing parenteral injectables and oral solid dosages indicated for Hodgkin's lymphoma, multiple myeloma, and breast carcinomas.
  • Immunology Therapeutics: Deployed extensively in the industrial production of high-specification treatments targeting severe lupus nephritis and systemic necrotizing vasculitis.
  • Transplantation Research: Utilized as a critical raw material by research institutions investigating conditioned immunosuppressive protocols in hematopoietic stem cell transplantation.
HPAPI SAFETY & SOURCING DIRECTIVE

Cyclophosphamide is classified as a highly potent cytotoxic active pharmaceutical ingredient (HPAPI) intended strictly for industrial pharmaceutical manufacturing and authorized scientific research under containment conditions. Because the powder is sensitive to ambient moisture (which induces hydrolysis of the chloroethyl groups and diminishes alkylating potency), strict storage in moisture-barrier packaging is mandatory to preserve the validated 24-month shelf life.

5. Frequently Asked Formulation Questions

Why is Cyclophosphamide classified and administered as a prodrug?
Cyclophosphamide in its raw form is pharmacologically inactive. This design intentionally minimizes direct gastrointestinal and mucosal toxicity upon initial administration. Its potent alkylating activity is only unlocked after hepatic oxidation by CYP450 enzymes, ensuring that the reactive nitrogen mustard effector is primarily generated in vivo.
How is the risk of hemorrhagic cystitis addressed in CTX formulations?
Hemorrhagic cystitis is caused by acrolein, a urinary metabolite of CTX that aggressively irritates the bladder urothelium. In clinical pharmaceutical protocols, CTX is frequently co-packaged or co-formulated with MESNA (Sodium 2-mercaptoethanesulfonate), a protective agent that chemically detoxifies acrolein within the urinary tract.
Is this API optimized for lyophilized powder for injection (LPI)?
Yes. Our high-purity Cyclophosphamide API features exceptionally low residual solvent levels and high crystalline uniformity. It is specifically optimized to withstand industrial freeze-drying cycles, yielding a robust cake structure with rapid reconstitution and flawless parenteral clarity.
Does Xi'an Tihealth provide technical documentation for regulatory filings?
Yes. We supply a comprehensive technical dossier with every commercial batch, including the Certificate of Analysis (COA), Method of Analysis (MOA), stability test data, and MSDS. Our regulatory affairs team is fully equipped to assist your partners with GMP audits and generic drug dossier submissions globally.

Hot Tags: cyclophosphamide powder cas no.50-18-0, China cyclophosphamide powder cas no.50-18-0 manufacturers, suppliers, factory, hialuronato de sodio hialuronato sodico sodium hyaluronate, , ,

Send Inquiry